EGFR-mutant lung adenocarcinomas mutation profiles reveal ARID1A might be a novel tyrosine kinase resistance pathway

被引：0
|
作者：
Gao, Xuyuan [1 ]
Xu, Hang [2 ]
Ho, James C. M. [3 ]
Chan, Oscar S. H. [4 ]
Xu, Feng [5 ]
Wang, Junwen [6 ]
Lee, Victor H. F. [7 ]
Tin, Vicky P. C. [1 ]
Xiao, Zhijie [1 ]
Wang, Siqi [1 ]
Yam, Judy W. P. [1 ]
Wong, Maria P. [1 ]
机构：
[1] Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China
[2] Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China
[3] Univ Hong Kong, Dept Med, Hong Kong, Peoples R China
[4] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[5] Univ British Columbia, St Pauls Hosp, Providence Hlth Care, Vancouver, BC, Canada
[6] Mayo Clin, Scottsdale, AZ USA
[7] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-LB-196
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-196
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors
    Landi, Lorenza
    Tiseo, Marcello
    Chiari, Rita
    Ricciardi, Serena
    Rossi, Elisa
    Galetta, Domenico
    Novello, Silvia
    Milella, Michele
    D'Incecco, Armida
    Minuti, Gabriele
    Tibaldi, Carmelo
    Salvini, Jessica
    Facchinetti, Francesco
    Haspinger, Eva Regina
    Cortinovis, Diego
    Santo, Antonio
    Banna, Giuseppe
    Catino, Annamaria
    GiajLevra, Matteo
    Crino, Lucio
    de Marinis, Filippo
    Cappuzzo, Federico
    CLINICAL LUNG CANCER, 2014, 15 (06) : 411 - 417
  • [42] Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancers that recur after adjuvant TKI
    Oxnard, G. R.
    Janjigian, Y. Y.
    Arcila, M. E.
    Kris, M. G.
    Ladanyi, M.
    Azzoli, C. G.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Overexpression of YAP1 of EGFR-mutant lung adenocarcinoma before tyrosine kinase inhibitor is associated with poor survival
    Hong, Soon Auck
    Kang, Jin-Hyoung
    Hong, Sook Hee
    CANCER RESEARCH, 2018, 78 (13)
  • [44] Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
    Sullivan, Ivana
    Planchard, David
    FRONTIERS IN MEDICINE, 2017, 3
  • [45] Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
    Kim, Soomin
    Koh, Jaemoon
    Kim, Tae Min
    Oh, Songji
    Kim, Soyeon
    Youk, Jeonghwan
    Kim, Miso
    Keam, Bhumsuk
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Heo, Dae Seog
    ISCIENCE, 2025, 28 (02)
  • [46] Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib
    Oxnard, Geoffrey R.
    Janjigian, Yelena Y.
    Arcila, Maria E.
    Sima, Camelia S.
    Kass, Samantha L.
    Riely, Gregory J.
    Pao, William
    Kris, Mark G.
    Ladanyi, Marc
    Azzoli, Christopher G.
    Miller, Vincent A.
    CLINICAL CANCER RESEARCH, 2011, 17 (19) : 6322 - 6328
  • [47] Dramatic Response to Afatinib in EGFR-Mutant Lung Adenocarcinomas After Resistance to First-Generation EGFR Inhibitors: A Brief Report
    Li, W.
    Yang, J.
    Chen, H.
    Li, A.
    Lin, J.
    Tu, H.
    Su, J.
    Zhang, X.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2221 - S2221
  • [48] ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas
    Song, Xiaoling
    Fan, Pang-Dian
    Bantikassegn, Amlak
    Guha, Udayan
    Threadgill, David W.
    Varmus, Harold
    Politi, Katerina
    CANCER RESEARCH, 2015, 75 (06) : 1035 - 1045
  • [49] Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma
    Bean, James
    Riely, Gregory J.
    Balak, Marissa
    Marks, Jenifer L.
    Ladanyi, Marc
    Miller, Vincent A.
    Pao, William
    CLINICAL CANCER RESEARCH, 2008, 14 (22) : 7519 - 7525
  • [50] JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
    Gao, Sizhi P.
    Chang, Qing
    Mao, Ninghui
    Daly, Laura A.
    Vogel, Robert
    Chan, Tyler
    Liu, Shu Hui
    Bournazou, Eirini
    Schori, Erez
    Zhang, Haiying
    Brewer, Monica Red
    Pao, William
    Morris, Luc
    Ladanyi, Marc
    Arcila, Maria
    Manova-Todorova, Katia
    De Stanchina, Elisa
    Norton, Larry
    Levine, Ross L.
    Altan-Bonnet, Gregoire
    Solit, David
    Zinda, Michael
    Huszar, Dennis
    Lyden, David
    Bromberg, Jacqueline F.
    SCIENCE SIGNALING, 2016, 9 (421)
12345